Fort Worth, TX, United States of America

Robert D Selliah


Average Co-Inventor Count = 1.7

ph-index = 4

Forward Citations = 153(Granted Patents)


Location History:

  • Ft. Worth, TX (US) (1998)
  • Cheshire, CT (US) (2000)
  • Fort Worth, TX (US) (1997 - 2002)
  • Forth Worth, TX (US) (2002)

Company Filing History:


Years Active: 1997-2002

Loading Chart...
11 patents (USPTO):Explore Patents

Title: The Innovations of Robert D. Selliah

Introduction

Robert D. Selliah is a notable inventor based in Fort Worth, Texas, recognized for his significant contributions to the field of ophthalmology. With a total of 11 patents to his name, he has made remarkable advancements in the treatment of glaucoma and ocular hypertension. His work has had a profound impact on the development of new therapeutic methods and pharmaceutical compositions.

Latest Patents

Among his latest patents, Selliah has developed "Substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives." This patent discloses methods for using these analogs in treating glaucoma and ocular hypertension. Another significant patent is the "Method of prostaglandin synthesis," which outlines techniques for synthesizing 9-Halo-13,14-dihydroprostaglandins that are useful in the treatment of these eye conditions. Additionally, he has disclosed ophthalmic pharmaceutical compositions that comprise such prostaglandins.

Career Highlights

Throughout his career, Selliah has worked with prominent companies in the pharmaceutical industry, including Alcon Laboratories, Inc. and Alcon Manufacturing, Ltd. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to innovative solutions for eye care.

Collaborations

Some of his notable coworkers include Peter G. Klimko and Mark R. Hellberg, who have also played significant roles in advancing research and development in ophthalmology.

Conclusion

Robert D. Selliah's contributions to the field of ophthalmology through his patents and collaborations have paved the way for new treatments for glaucoma and ocular hypertension. His innovative work continues to influence the industry and improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…